Home » Fitness, Health & Medicine, Manufacturing & Industry, Pharmaceuticals & Biotech, Services » China Biosimilars Market Share, Size, Growth, Analysis, Trends & Forecast From 2016 to 2022: Hexa Reports
“Get key Market Research Reports and Insightful Company Profiles”
Deep Research Report On Healthcare sector, “Biosimilars “ provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars and guide you use the Chinese trial venues to keep biosimilars development lean and to smoothly operate in China.

Synopsis 

Responding to strong desire of overseas and multinational pharmaceutical manufacturers and domestic pharmaceutical manufacturers to carry out research and development of biosimilar products, this is first time in history, Chinese pharmaceutical authorities, China Food and Drug Administration officially issued a technical guidance for development and evaluation of biosimilars and defined the pathway of license approval for biosimilars. Chinese pharmaceutical authorities require that when conducting the research and development of biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in compliance with the Guidance and follow the pathway of license approval of biosimilars. 

Browse Detail Report With TOC @

http://www.hexareports.com/report/latest-chinese-guidance-for-development-evaluation-license-approval-of-biosimilars/details 

Summary

China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical data shows 40 per cent of China’s $1.5bn recombinant biologic product sales come from biosimilars, which have enjoyed approximately 25-30 per cent CAGR over the past decade. If the market continues to grow at 25 per cent per year, the biosimilar market could grow to $2bn, around 20 per cent of the global biosimilar market by 2015. It is attracting more and more overseas and multinational pharmaceutical manufacturers and producers to penetrate such market. 

Request A Sample copy of This Report @

http://www.hexareports.com/sample/50888 

Reason To Buy

China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical data shows 40 per cent of China’s $1.5bn recombinant biologic product sales come from biosimilars, which have enjoyed approximately 25-30 per cent CAGR over the past decade. If the market continues to grow at 25 per cent per year, the biosimilar market could grow to $2bn, around 20 per cent of the global biosimilar market by 2015. 

This is first time in history, Chinese pharmaceutical authorities, China Food and Drug Administration officially issued a technical guidance for development and evaluation of biosimilars and defined the pathway of license approval for biosimilars. Chinese pharmaceutical authorities require that when conducting the research and development of biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in compliance with the Guidance and follow the pathway of license approval of biosimilars.

How to grasp the opportunity to smoothly conduct the research and development of biosimilar products in China and speed up your biosimilar product approval time? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars. 

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars and guide you use the Chinese trial venues to keep biosimilars development lean and to smoothly operate in China. 

Key Highlights

The applicable scope of Guidance.

An overview of general principles of development and evaluation of biosimilar products in China.

The detailed requirements for research and evaluation of pharmacy.

The detailed requirements for non-clinical research and evaluation.

The detailed requirements for clinical research and evaluation, from clinical pharmacology study covering pharmacokinetics study, pharmacodynamics study and (PK/PD) study, efficacy study, safety study, immunogenicity study to extrapolation of indications to smoothly navigate complex regulatory requirements step by step.

An overview of marketing license approval of biosimilars in China, from Chinas registration category of biological products, specific pathway of license approval for imported biosimilar registration to application dossiers and data for license approval of biological products to guide you achieve a successful entry into the Chinese drug market, and smoothly operate your biosimilar products in China.

Chinas Application Form of Drug Registration in English. 

Browse Some “Healthcare Market” Research Reports 

Next Generation Cancer Diagnostics Market @

http://www.hexareports.com/report/next-generation-cancer-diagnostics-market/details 

Glucose Biosensor Market 2022 @

http://www.hexareports.com/report/glucose-biosensor-market-size-forecast/details

 Healthcare Cognitive Computing Industry @

http://www.hexareports.com/report/healthcare-cognitive-computing-market/details 

About Us:

Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: sales@hexareports.com
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/latest-chinese-guidance-for-development-evaluation-license-approval-of-biosimilars/details

Comments are closed.